Cullinan Oncology Inc
NASDAQ:CGEM
Intrinsic Value
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CGEM.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Cullinan Oncology Inc's business.
What risks and challenges
does Cullinan Oncology Inc face in the near future?
Summarize the latest earnings report
of Cullinan Oncology Inc.
Provide P/E
for Cullinan Oncology Inc and its competitors.
Balance Sheet Decomposition
Cullinan Oncology Inc
Current Assets | 480.2m |
Cash & Short-Term Investments | 467.1m |
Other Current Assets | 13.1m |
Non-Current Assets | 4m |
PP&E | 3.5m |
Other Non-Current Assets | 459k |
Current Liabilities | 28.1m |
Accounts Payable | 2.5m |
Accrued Liabilities | 25.6m |
Non-Current Liabilities | 2.3m |
Other Non-Current Liabilities | 2.3m |
Earnings Waterfall
Cullinan Oncology Inc
Revenue
|
0
USD
|
Operating Expenses
|
-190.6m
USD
|
Operating Income
|
-190.6m
USD
|
Other Expenses
|
37.5m
USD
|
Net Income
|
-153.2m
USD
|
Free Cash Flow Analysis
Cullinan Oncology Inc
What is Free Cash Flow?
CGEM Profitability Score
Profitability Due Diligence
Cullinan Oncology Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Cullinan Oncology Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
CGEM Solvency Score
Solvency Due Diligence
Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CGEM Price Targets Summary
Cullinan Oncology Inc
According to Wall Street analysts, the average 1-year price target for CGEM is 26.01 USD with a low forecast of 19.19 USD and a high forecast of 35.7 USD.
Ownership
CGEM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CGEM Price
Cullinan Oncology Inc
Average Annual Return | -40.05% |
Standard Deviation of Annual Returns | 6.82% |
Max Drawdown | -86% |
Market Capitalization | 731m USD |
Shares Outstanding | 43 065 600 |
Percentage of Shares Shorted | 2.01% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.